New York State Teachers Retirement System Trims Holdings in Gilead Sciences, Inc. $GILD

New York State Teachers Retirement System decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% during the third quarter, HoldingsChannel.com reports. The firm owned 1,094,150 shares of the biopharmaceutical company’s stock after selling 29,735 shares during the period. New York State Teachers Retirement System’s holdings in Gilead Sciences were worth $121,451,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in GILD. Rothschild Investment LLC lifted its holdings in shares of Gilead Sciences by 1.9% in the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after buying an additional 84 shares in the last quarter. Hemington Wealth Management boosted its holdings in Gilead Sciences by 9.3% in the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 85 shares during the period. Ignite Planners LLC grew its position in shares of Gilead Sciences by 1.1% during the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after purchasing an additional 86 shares in the last quarter. Archer Investment Corp increased its holdings in shares of Gilead Sciences by 1.2% in the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock worth $807,000 after purchasing an additional 87 shares during the period. Finally, Binnacle Investments Inc increased its holdings in shares of Gilead Sciences by 14.3% in the second quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 88 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of several recent analyst reports. TD Cowen boosted their target price on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. HSBC upped their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research report on Wednesday, December 10th. Morgan Stanley lifted their target price on shares of Gilead Sciences from $147.00 to $151.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Rothschild & Co Redburn increased their price target on shares of Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $133.20.

Gilead Sciences Trading Up 0.4%

Shares of GILD opened at $121.10 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $88.57 and a fifty-two week high of $128.70. The firm has a market cap of $150.25 billion, a price-to-earnings ratio of 18.78, a PEG ratio of 0.64 and a beta of 0.33. The firm has a 50 day moving average price of $123.27 and a 200-day moving average price of $117.59. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were given a $0.79 dividend. The ex-dividend date was Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.6%. Gilead Sciences’s payout ratio is presently 48.99%.

Insider Activity

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the sale, the director owned 1,339 shares of the company’s stock, valued at $170,186.90. This represents a 67.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at $1,115,713.60. The trade was a 35.92% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 136,257 shares of company stock valued at $16,855,192. Corporate insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.